Cargando…

Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)

Pretomanid is a promising anti-tubercular drug currently at clinical phase III, but its mechanisms of action are currently unclear. This study aimed to: (i) reveal the metabolome of Mycobacterium smegmatis under pretomanid treatment; (ii) compare major sources of metabolite variation in bacteria tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baptista, Rafael, Fazakerley, David M., Beckmann, Manfred, Baillie, Les, Mur, Luis A. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865180/ https://www.ncbi.nlm.nih.gov/pubmed/29572459 http://dx.doi.org/10.1038/s41598-018-23110-1

Ejemplares similares

Untargeted Metabolomics To Ascertain Antibiotic Modes of Action
por: Vincent, Isabel M., et al.
Publicado: (2016)

Untargeted Metabolomic Profiling Reveals Variation in Metabolites Associated with Nutritional Values in Tef Accessions
por: Girija, Aiswarya, et al.
Publicado: (2021)

The R Enantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral Leishmaniasis
por: Patterson, Stephen, et al.
Publicado: (2013)

Untargeted metabolomic analysis of thoracic blood from badgers indicate changes linked to infection with bovine tuberculosis (Mycobacterium bovis): a pilot study
por: Bauman, James Scott, et al.
Publicado: (2022)

Structure of Ddn, the Deazaflavin-Dependent Nitroreductase from Mycobacterium tuberculosis Involved in Bioreductive Activation of PA-824
por: Cellitti, Susan E., et al.
Publicado: (2012)

Structure of Ddn, the Deazaflavin-Dependent Nitroreductase from Mycobacterium tuberculosis Involved in Bioreductive Activation of PA-824
por: Cellitti, Susan E., et al.
Publicado: (2013)

Untargeted metabolomic analysis of miltefosine action in Leishmania infantum reveals changes to the internal lipid metabolism()
por: Vincent, Isabel M., et al.
Publicado: (2013)

Unravelling Plant Responses to Stress—The Importance of Targeted and Untargeted Metabolomics
por: Allwood, James William, et al.
Publicado: (2021)

Population Pharmacokinetics of the Antituberculosis Agent Pretomanid
por: Salinger, David H., et al.
Publicado: (2019)

Delamanid or pretomanid? A Solomonic judgement!
por: Mudde, Saskia E., et al.
Publicado: (2022)

Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid
por: Timm, Juliano, et al.
Publicado: (2023)

An Exposure-Response Perspective on the Clinical Dose of Pretomanid
por: Nedelman, Jerry R., et al.
Publicado: (2020)

Male reproductive hormones in patients treated with pretomanid
por: Boekelheide, K., et al.
Publicado: (2022)

Pretomanid for tuberculosis treatment: an update for clinical purposes
por: Occhineri, Sara, et al.
Publicado: (2022)

1400. Pretomanid in the Treatment of Patients with Tuberculosis in the United States: the Bedaquiline, Pretomanid and Linezolid (BPaL) Accelerated Monitoring (BAM) Project
por: Goswami, Neela, et al.
Publicado: (2021)

Cordyceps sinensis promotes immune regulation and enhances bacteriostatic activity of PA-824 via IL-10 in Mycobacterium tuberculosis disease
por: Li, D.G., et al.
Publicado: (2017)

Comparison of in vitro Susceptibility of Mycobacteria Against PA-824 to Identify Key Residues of Ddn, the Deazoflavin-Dependent Nitroreductase from Mycobacterium tuberculosis
por: Zhang, Fuzhen, et al.
Publicado: (2020)

Integration of untargeted metabolomics with transcriptomics reveals active metabolic pathways
por: Cho, Kyuil, et al.
Publicado: (2014)

Metabolic Alterations in Preneoplastic Development Revealed by Untargeted Metabolomic Analysis
por: Myllymäki, Henna, et al.
Publicado: (2021)

Untargeted NMR Metabolomics Reveals Alternative Biomarkers and Pathways in Alkaptonuria
por: Grasso, Daniela, et al.
Publicado: (2022)

Untargeted Metabolomics Reveals Alterations of Rhythmic Pulmonary Metabolism in IPF
por: Sun, Wei, et al.
Publicado: (2023)

Identification and metabolomic characterization of potent anti-MRSA phloroglucinol derivatives from Dryopteris crassirhizoma Nakai (Polypodiaceae)
por: Bhowmick, Sumana, et al.
Publicado: (2022)

Untargeted Metabolomics Reveals New Markers of Food Processing for Strawberry and Apple Purees
por: Salazar-Orbea, Gabriela, et al.
Publicado: (2022)

Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis
por: Velásquez, Gustavo E., et al.
Publicado: (2023)

The Differential Gene Expression Pattern of Mycobacterium tuberculosis in Response to Capreomycin and PA-824 versus First-Line TB Drugs Reveals Stress- and PE/PPE-Related Drug Targets
por: Fu, Li M., et al.
Publicado: (2009)

Corrigendum: Identification and metabolomic characterization of potent anti-MRSA phloroglucinol derivatives from Dryopteris crassi rhizoma Nakai (Polypodiaceae)
por: Bhowmick, Sumana, et al.
Publicado: (2023)

Non-Targeted Metabolite Profiling Reveals Host Metabolomic Reprogramming during the Interaction of Black Pepper with Phytophthora capsici
por: Kattupalli, Divya, et al.
Publicado: (2021)

Untargeted metabolomic profiling of Sphagnum fallax reveals novel antimicrobial metabolites
por: Fudyma, Jane D., et al.
Publicado: (2019)

Untargeted Metabolomics Reveals the Effect of Selective Breeding on the Quality of Chicken Meat
por: Shi, Kai, et al.
Publicado: (2022)

Untargeted metabolomics reveal rhizosphere metabolites mechanisms on continuous ramie cropping
por: Fu, Yafen, et al.
Publicado: (2023)

Untargeted Metabolomics Reveals Major Differences in the Plasma Metabolome between Colorectal Cancer and Colorectal Adenomas
por: Gumpenberger, Tanja, et al.
Publicado: (2021)

Rapid Evaluation in Whole Blood Culture of Regimens for XDR-TB Containing PNU-100480 (Sutezolid), TMC207, PA-824, SQ109, and Pyrazinamide
por: Wallis, Robert S., et al.
Publicado: (2012)

Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor
por: Somasundaram, Sulochana, et al.
Publicado: (2013)

Untargeted Metabolomic Characterization of Ovarian Tumors
por: Liu, Xiaona, et al.
Publicado: (2020)

Editorial: Advances and challenges in untargeted metabolomics
por: Wawrzyniak, Renata, et al.
Publicado: (2023)

PA01.33. Mode of action of medhya drugs: A review
por: Mehra, Bhawana, et al.
Publicado: (2012)

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
por: Tweed, C. D., et al.
Publicado: (2021)

Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date
por: Stancil, Stephani L, et al.
Publicado: (2021)

Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid
por: Bateson, Anna, et al.
Publicado: (2022)

Toxicity and toxicokinetic assessment of an anti-tubercular drug pretomanid in cynomolgus monkeys
por: Bruning-Barry, Rebecca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c5t8l0rsn32b5e347931c8nqtl